1. Home
  2. ANDE vs ANAB Comparison

ANDE vs ANAB Comparison

Compare ANDE & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Andersons Inc. (The)

ANDE

Andersons Inc. (The)

HOLD

Current Price

$59.50

Market Cap

1.7B

Sector

Industrials

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$47.57

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANDE
ANAB
Founded
1947
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.4B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
ANDE
ANAB
Price
$59.50
$47.57
Analyst Decision
Strong Buy
Buy
Analyst Count
3
12
Target Price
$58.33
$60.18
AVG Volume (30 Days)
259.3K
489.7K
Earning Date
02-17-2026
02-26-2026
Dividend Yield
1.33%
N/A
EPS Growth
N/A
N/A
EPS
2.13
N/A
Revenue
$11,595,817,000.00
$169,467,000.00
Revenue This Year
$6.45
$135.51
Revenue Next Year
$3.37
N/A
P/E Ratio
$28.27
N/A
Revenue Growth
2.19
196.42
52 Week Low
$31.03
$12.21
52 Week High
$62.10
$52.47

Technical Indicators

Market Signals
Indicator
ANDE
ANAB
Relative Strength Index (RSI) 64.61 54.75
Support Level $56.96 $44.25
Resistance Level $62.10 $48.53
Average True Range (ATR) 1.68 2.96
MACD 0.46 -0.20
Stochastic Oscillator 74.61 66.35

Price Performance

Historical Comparison
ANDE
ANAB

About ANDE Andersons Inc. (The)

Andersons Inc is a diversified company with its main focus in the agriculture sector. Its operations are segmented into Trade, Renewables, and Nutrient & Industrial. The Trade segment, which generates the majority of the revenue, is engaged in the movement of physical commodities such as whole grains, grain products, feed ingredients, and domestic fuel products, among other agricultural commodities. Geographically, the company generates the majority of its revenue from the United States and the rest from Canada, Mexico, Egypt, Switzerland, and other markets.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: